AMSTERDAM, Netherlands—Some patients with breast cancer could soon be treated with surgery and targeted drugs without the need for chemotherapy—according to findings reported at the 2016 European Brea
AMSTERDAM, Netherlands—Some patients with breast cancer could soon be treated with surgery and targeted drugs without the need for chemotherapy—according to findings reported at the 2016 European Breast Cancer Conference by Judith Bliss, Professor of Clinical Trials at the Institute of Cancer Research, in Sutton, near London UK.
Patients whose cancers tested positive for the HER2 molecule responded in matter of days to a combination of the two drugs lapatinib plus trastuzumab used in the brief window between diagnosis and surgery in the UK EPHOS B study—indicating that such anti-HER2 drug combinations could be effective in the months following surgery—avoiding cytotoxic side effects such as hair loss and increased risk of heart disease.
SOURCE:
http://www.ecco-org.eu/Events/EBCC10/…
Abstract 6LB:
“Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer – the UK EPHOS-B trial (CRUK/08/002)”
AJO Cancer Spotlight: Posted April 5th, 2016 By the Audio Journal of Oncology